首页> 美国卫生研究院文献>other >Confinement-Induced Drug-Tolerance in Mycobacteria Mediated by an Efflux Mechanism
【2h】

Confinement-Induced Drug-Tolerance in Mycobacteria Mediated by an Efflux Mechanism

机译:分流机制介导的分枝杆菌的禁闭诱导药物耐受

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tuberculosis (TB) is the world’s deadliest curable disease, responsible for an estimated 1.5 million deaths annually. A considerable challenge in controlling this disease is the prolonged multidrug chemotherapy (6 to 9 months) required to overcome drug-tolerant mycobacteria that persist in human tissues, although the same drugs can sterilize genetically identical mycobacteria growing in axenic culture within days. An essential component of TB infection involves intracellular Mycobacterium tuberculosis bacteria that multiply within macrophages and are significantly more tolerant to antibiotics compared to extracellular mycobacteria. To investigate this aspect of human TB, we created a physical cell culture system that mimics confinement of replicating mycobacteria, such as in a macrophage during infection. Using this system, we uncovered an epigenetic drug-tolerance phenotype that appears when mycobacteria are cultured in space-confined bioreactors and disappears in larger volume growth contexts. Efflux mechanisms that are induced in space-confined growth environments contribute to this drug-tolerance phenotype. Therefore, macrophage-induced drug tolerance by mycobacteria may be an effect of confined growth among other macrophage-specific mechanisms.
机译:结核病(TB)是世界上最致命的可治愈疾病,估计每年造成150万人死亡。控制这种疾病面临的一项巨大挑战是,需要长期的多药化疗(6至9个月),以克服在人体组织中持续存在的耐药性分枝杆菌,尽管相同的药物可以在几天之内对在无菌培养物中生长的遗传上相同的分枝杆菌进行灭菌。结核感染的重要组成部分涉及细胞内结核分枝杆菌细菌,该细菌在巨噬细胞内繁殖,并且与细胞外分枝杆菌相比,对抗生素的耐受性明显更高。为了研究人类结核病的这一方面,我们创建了一个物理细胞培养系统,该系统模仿复制分枝杆菌的限制,例如在感染过程中在巨噬细胞中。使用该系统,我们发现了表观遗传学药物耐受表型,当分枝杆菌在空间受限的生物反应器中培养时出现,并在更大的体积增长环境中消失。在空间受限的生长环境中诱导的外排机制有助于这种药物耐受表型。因此,分枝杆菌对巨噬细胞诱导的药物耐受性可能是其他巨噬细胞特异性机制中局限性生长的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号